- Sections
- C - Chimie; métallurgie
- C07D - Composés hétérocycliques
- C07D 295/215 - Radicaux dérivés d'analogues azotés de l'acide carbonique
Détention brevets de la classe C07D 295/215
Brevets de cette classe: 99
Historique des publications depuis 10 ans
|
8
|
7
|
8
|
3
|
3
|
7
|
9
|
8
|
7
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Janssen Pharmaceutica N.V. | 3624 |
5 |
| Excir Works Corp. | 29 |
4 |
| Boehringer Ingelheim International GmbH | 4756 |
2 |
| Ricoh Company, Ltd. | 13205 |
2 |
| Chong Kun Dang Pharmaceutical Corp. | 237 |
2 |
| The Florida International University Board of Trustees | 580 |
2 |
| Heliatek GmbH | 130 |
2 |
| Immunomet Therapeutics Inc. | 29 |
2 |
| Janssen Biotech, Inc. | 1464 |
2 |
| Merial, Inc. | 225 |
2 |
| Nabriva Therapeutics AG | 23 |
2 |
| The United States of America, as represented by the Secretary, Department of Health & Human Services | 210 |
2 |
| Universita degli Studi di Milano-bicocca | 153 |
2 |
| Universita' degli Studi di Pavia | 72 |
2 |
| Viamet Pharmaceuticals, Inc. | 39 |
2 |
| Chengdu Kaoensi Science and Technology Co., Ltd. | 2 |
2 |
| Corteva Agriscience LLC | 2680 |
2 |
| Chorda Pharma, Inc. | 5 |
2 |
| Reata Pharmaceuticals Holdings, LLC | 46 |
2 |
| Bristol-myers Squibb Company | 4883 |
1 |
| Autres propriétaires | 55 |